FDA Clears Groundbreaking New Treatments for Metastatic Pancreatic Cancer and Diabetes Monitoring
The FDA has approved the first in-class targeted therapy for metastatic pancreatic cancer, marking a significant breakthrough in the fight against the disease.[239106][340606]
The FDA has also authorized the first wearable device to continuously monitor ketone and glucose levels, which may provide earlier warning of metabolic deterioration for patients with diabetes.[63294][45681]
The FDA has cleared the first Alzheimer's blood test for symptomatic patients as young as 40, offering a new tool for early detection and treatment of the disease.[2499]